IRIS
NATOLI, Clara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.592
EU - Europa 8.743
AS - Asia 6.653
SA - Sud America 829
AF - Africa 98
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 7
AN - Antartide 1
Totale 26.942
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.433
SG - Singapore 2.842
RU - Federazione Russa 2.705
CN - Cina 1.802
IE - Irlanda 1.026
IT - Italia 945
UA - Ucraina 914
SE - Svezia 792
FR - Francia 714
BR - Brasile 672
GB - Regno Unito 666
TR - Turchia 643
VN - Vietnam 615
DE - Germania 482
IN - India 278
FI - Finlandia 168
HK - Hong Kong 106
CA - Canada 78
AT - Austria 62
AR - Argentina 57
PL - Polonia 57
MX - Messico 55
JP - Giappone 52
BD - Bangladesh 51
BE - Belgio 50
IQ - Iraq 48
NL - Olanda 32
ZA - Sudafrica 31
CZ - Repubblica Ceca 30
ES - Italia 28
PK - Pakistan 27
SA - Arabia Saudita 21
KR - Corea 20
EG - Egitto 19
CO - Colombia 18
UZ - Uzbekistan 18
EU - Europa 17
EC - Ecuador 16
CL - Cile 15
ID - Indonesia 15
PH - Filippine 15
VE - Venezuela 14
AE - Emirati Arabi Uniti 13
AL - Albania 12
LT - Lituania 12
PY - Paraguay 12
RO - Romania 12
JO - Giordania 10
MA - Marocco 10
BO - Bolivia 9
IL - Israele 9
KE - Kenya 9
LB - Libano 9
PE - Perù 9
TN - Tunisia 8
AU - Australia 7
DZ - Algeria 7
IR - Iran 7
UY - Uruguay 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
NP - Nepal 6
CH - Svizzera 5
GR - Grecia 5
OM - Oman 5
SN - Senegal 5
TH - Thailandia 5
DK - Danimarca 4
ET - Etiopia 4
GT - Guatemala 4
PT - Portogallo 4
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
JM - Giamaica 3
KG - Kirghizistan 3
MT - Malta 3
MY - Malesia 3
NI - Nicaragua 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AM - Armenia 2
BH - Bahrain 2
CI - Costa d'Avorio 2
DM - Dominica 2
HN - Honduras 2
HU - Ungheria 2
KW - Kuwait 2
KZ - Kazakistan 2
MM - Myanmar 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
Totale 26.930
Salva come PNG Salva come JPEG
Città #
Singapore 2.168
Chandler 1.479
Jacksonville 1.168
San Jose 1.068
Dublin 1.016
Ashburn 729
Dallas 557
Beijing 471
Princeton 466
Southend 414
Izmir 378
Nanjing 342
Los Angeles 283
Wilmington 225
Ho Chi Minh City 199
The Dalles 196
Santa Clara 193
Dearborn 189
Ann Arbor 177
Cambridge 174
Altamura 167
New York 164
Boardman 148
Chieti 140
Nanchang 126
Hanoi 122
Buffalo 115
Tongling 111
Munich 103
Hong Kong 93
Woodbridge 93
Houston 91
Moscow 81
São Paulo 71
Redondo Beach 70
Dong Ket 68
Shenyang 63
Hebei 60
Council Bluffs 58
Orem 58
Kunming 54
Rome 52
Tianjin 51
Brussels 48
Tokyo 46
Vienna 45
Brooklyn 44
Warsaw 44
Washington 44
Chicago 41
Jiaxing 40
London 39
Norwalk 38
Nuremberg 37
Atlanta 35
Denver 34
Milan 34
Montreal 34
Frankfurt am Main 33
Stockholm 32
Pescara 31
Boston 30
Da Nang 29
Helsinki 28
Hyderabad 28
Chennai 26
Johannesburg 25
Seattle 25
Changsha 23
Poplar 23
Brno 22
Falls Church 22
Haiphong 22
Mumbai 22
Hangzhou 21
Manchester 21
San Francisco 21
Belo Horizonte 20
Hefei 20
Mexico City 20
Phoenix 20
Rio de Janeiro 20
Kocaeli 19
Seoul 19
Amsterdam 18
Baghdad 18
Toronto 18
San Mateo 17
Lanzhou 16
St Louis 16
Tashkent 16
Turku 16
Düsseldorf 15
Auburn Hills 14
Augusta 14
Shanghai 14
Tappahannock 14
Cairo 13
Changchun 13
Dhaka 13
Totale 15.521
Salva come PNG Salva come JPEG
Nome #
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 855
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 836
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 767
45: L’UTILIZZO DELL’IMMUNOTERAPIA PER IL TRATTAMENTO DELL’ADENOCARCINOMA POLMONARE IN II LINEA: NIVOLUMAB VS PEMBROLIZUMAB 277
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 205
90K (Mac-2 BP) in human milk 197
Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer 186
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 182
A multidisciplinary group for prostate cancer management: A single institution experience 182
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 174
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 172
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 171
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 170
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 165
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 164
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 163
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 158
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 158
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 157
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 157
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 157
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patients survival. 156
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 155
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 153
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 153
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 152
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 152
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 151
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 150
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 149
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 149
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 147
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 145
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 145
New Targets for Therapy in Pancreatic Cancer 144
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 143
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 143
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 142
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 142
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 140
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 139
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 138
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 137
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 137
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 137
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 133
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 133
Chemotherapy preoperative for the management of breast cancer locally advanced 132
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 132
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 130
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 130
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 130
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 128
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 128
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 127
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 127
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 127
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 127
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 127
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 125
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 125
A Flow cytometric study of early gastric cancer 125
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 125
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 125
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 125
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 124
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 124
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 123
Interleukin-30 Promotes Breast Cancer Growth and Progression 123
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 123
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 123
Principali effetti collaterali delle terapie mediche 122
DNA ploidy and S-phase fraction in pulmonary carcinoids. 121
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 121
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 121
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer 121
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 121
Prognostic value of 90K protein in HIV infection 120
Surgical treatment of adrenal metastases from non small cell lung cancer 120
Tyrosine kinase inhibitors 120
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 120
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 120
Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-centre study 119
Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study 119
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 117
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 116
Unknown primary tumors 116
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 116
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 116
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 116
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 115
Tumor-derived microvesicles: The metastasomes. 115
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 115
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 115
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 115
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 115
Prognostic value of a novel circulating serum 90K antigen in breast cancer 114
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 114
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy 114
Totale 15.893
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.436
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.436
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021365 0 0 0 0 0 0 0 0 0 151 84 130
2021/20221.092 23 33 8 193 114 26 23 69 78 28 131 366
2022/20233.858 310 474 269 470 390 717 200 328 445 37 133 85
2023/20241.589 130 55 119 47 126 552 286 49 25 49 16 135
2024/20253.673 202 692 532 115 86 173 137 218 355 188 418 557
2025/20269.885 674 378 979 925 838 588 1.529 495 2.812 667 0 0
Totale 27.789